Printer Friendly

Lannett signs settlement and license agreement with Celgene.

M2 PHARMA-November 1, 2017-Lannett signs settlement and license agreement with Celgene

(C)2017 M2 COMMUNICATIONS

United States-based Lannett has signed a settlement and license agreement with United States-based Celgene.

It was reported yesterday that the contract resolves patent infringement litigation in the United States related to Celgene's Thalomid.

The license agreement approves Lannett to produce and market its generic thalidomide product in the United States as of 1 August 2019 or earlier under certain circumstances. As mandated by the US Food and Drug Administration (FDA), Thalomid is subject to Risk Evaluation and Mitigation Strategies program, which is designed and implemented during the commercialisation of a pharmaceutical product to ensure an acceptable risk-to-benefit ratio for products that are known to exhibit specific risks. Subject to FDA approval of Lannett's Abbreviated New Drug Application (ANDA) for Thalidomide, the company intends to launch its product under the terms of the license agreement, which are confidential.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 1, 2017
Words:163
Previous Article:US Food and Drug Administration approves new dosing for Janssen Pharmaceuticals' Xarelto.
Next Article:Novartis to acquire Advanced Accelerator Applications.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters